Abstract: The subject invention encompasses methods and compositions comprising phosphate derivatives of triclosan for treating or preventing dental plaque, gingivitis or periodontal disease, of the oral cavity in humans or lower animals.

Abstract: The present invention relates to quaternary nitrogen-containing phosphonate compounds, and the pharmaceutically-acceptable salts and esters thereof and having the general structure: ##STR1## wherein R.sup.1, R.sup.2, R.sup.5 and R.sup.8 are defined in claim 1, m and n are integers from 0 to 10; m+n is from 0 to 10;Z is a saturated, unsaturated, or aromatic, monocyclic or polycyclic carbocycle or monocyclic or polycyclic heterocycle containing one or more heteroatoms selected from O, S, or N, wherein at least one heteroatom is a quaternary nitrogen atom;R is COOH; PO.sub.3 H.sub.2 ; SO.sub.3 H; or P(O)(OH)R.sub.4, wherein R.sub.4 is substituted or unsubstituted alkyl of 1-8 carbon atoms;The present invention further relates to pharmaceutical compositions containing a safe and effective amount of a compound of the present invention, and pharmaceutically-acceptable excipients.

Abstract: Compositions for inhibiting the anomalous mobilization of calcium phosphates in animal tissue comprising an effective amount of certain phosphonate compounds as herein defined in combination with Vitamin D-like antirachitic compounds, and a method for treating or preventing conditions involving hard tissue demineralization in an animal comprising concurrently administering said phosphonates and Vitamin D-like antirachitic compounds to animals.

Abstract: The anti-inflammatory activity of fenoprofen, ketoprofen, MK-830 and other phenylacetic acid-based anti-inflammatory drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Abstract: The anti-inflammatory activity of aspirin and other salicylate-based, anti-inflammatory drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Abstract: The anti-inflammatory activity of indomethacin, indoxole, and other indole-based drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Abstract: The anti-inflammatory activity of ibuprofen, ibufenac and other p-(isobutylphenyl)acetic acid-based anti-inflammatory drugs is enhanced by adminstration thereof in conjuction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Abstract: Technetium-99m has ideal characteristics for imaging the upper and lower GI tract and determining stomach emptying and intestinal transit time when used with an insoluble particulate material. For example, crystalline and amorphous calcium phosphate particles can be effectively labeled in a one-step process using .sup.99m TcO.sub.4 and SnCl.sub.2. These labeled particles have insignificant mass and when administered orally pass through the GI tract unchanged, without affecting the handling and density of the intestinal contents. Visualization of the esophageal entry into the stomach, the greater and lesser curvatures of the stomach, ejection into the duodenum, and rates of passage through the upper and lower GI tract are obtained. The slurry of .sup.99m Tc particulate can be given rectally by enema. Good images of the cecum and the ascending, transverse, and descending colon are obtained. Mucosa folds and the splenic and hepatic flexures are visualized.

Abstract: A composition and method for the preparation of a technetium-99 m based scintigraphic scanning agent are disclosed. The agent is prepared by the addition of a pertechnetate-99 m solution to an anhydrous salt composition comprising a phosphonic acid or a pharmaceutically acceptable salt thereof and a non-toxic, water-soluble, anhydrous, stannous, ferrous or chromous salt of hydrochloric or sulfuric acid.

Abstract: Compositions for inhibiting the anomalous mobilization of calcium phosphates in animal tissue comprising an effective amount of certain phosphonate compounds as herein defined in combination with Vitamin D-like antirachitic compounds, and a method for treating or preventing conditions involving hard tissue demineralization in an animal comprising concurrently administering said phosphonates and Vitamine D-like antirachitic compounds to animals.

Abstract: The anti-inflammatory activity of phenylbutazone, oxyphenbutazone, and other pyrazolidine-based anti-inflammatory drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Abstract: Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.

Abstract: Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.